Invention Grant
- Patent Title: Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease
-
Application No.: US16369966Application Date: 2019-03-29
-
Publication No.: US11241395B2Publication Date: 2022-02-08
- Inventor: Joachim Struck , Andreas Bergmann
- Applicant: B.R.A.H.M.S. GmbH
- Applicant Address: DE Henningsdorf
- Assignee: B.R.A.H.M.S. GmbH
- Current Assignee: B.R.A.H.M.S. GmbH
- Current Assignee Address: DE Henningsdorf
- Agency: Millen White Zelano and Branigan, PC
- Agent John Sopp
- Priority: EP07015271 20070803,EP08152651 20080312
- Main IPC: G01N31/00
- IPC: G01N31/00 ; G01N33/53 ; A61K31/00 ; G01N33/68 ; G01N33/74

Abstract:
In vitro methods such as in vitro diagnosis, prognosis and risk stratification of a patient having a primary disease, whereby the level of Procalcitonin (PCT) or fragment thereof in a sample of a bodily fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition. Assays for performing such methods and samples containing complex resulting from such methods.
Public/Granted literature
Information query